|[November 09, 2012]
WeissLaw LLP Investigates Dusa Pharmaceuticals Inc.
NEW YORK --(Business Wire)--
WeissLaw LLP, a national class action and shareholder rights law firm
with offices in New York City and Los Angeles, is investigating possible
breaches of fiduciary duty and other violations of law by the Board of
Directors of Dusa Pharmaceuticals Inc. (NASDAQ: DUSA) arising from its
agreement for Dusa to be acquired by Sun Pharmaceuticals Industries
Ltd., in a cash deal valued at approximately $230 million. Dusa
shareholders will receive $8.00 per share.
WeissLaw LLP is investigating whether Dusa's Board is acting to maximize
shareholder value for Dusa's public shareholders in approving this deal
and whether the Board engaged in a robust sale process in shopping the
company. The $8.00 per share offer price is approximately 15% less than
the $9.50 per share price target set by n analyst. If you own Dusa
shares and would like more information about your rights as a
shareholder or additional information concerning our investigation,
please contact Michael A. Rogovin either by email at email@example.com
or by telephone at (888) 593-4771.
WeissLaw LLP has litigated hundreds of stockholder class and derivative
actions for violations of corporate and fiduciary duties. We have
recovered over a billion dollars for defrauded institutions and
individuals and obtained important corporate governance in these cases.
If you have information or would like legal advice concerning possible
corporate wrongdoing (including insider trading, waste of corporate
assets, accounting fraud, or issuing materially misleading information),
consumer fraud (including false advertising, defective products, or
other deceptive business practices), or anti-trust violations, please
email us at firstname.lastname@example.org
or fill out the form on our website, http://www.weisslawllp.com/contact/report_fraud/.
Attorney Advertising. Past results do not guarantee a similar outcome.
[ Back To Technology News's Homepage ]